Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MorphoSys and Boehringer Ingelheim have entered into a biopharmaceutical manufacturing pact for therapeutic antibodies.
Subscribe to our email newsletter
Under the agreement, the companies will work on process development and manufacturing for MorphoSys’ proprietary MOR208 program and other drug candidates.
MOR208 is a monoclonal anti-CD19 antibody is in development as a treatment for chronic lymphocytic leukemia and potentially other B-cell malignancies.
MorphoSys chief scientific officer Marlies Sproll said adding an additional supplier to their proprietary development set-up will help to prevent any bottlenecks in clinical trial supply in the years ahead.
"Additionally, establishing a commercial manufacturing process with Boehringer Ingelheim early in the development of MOR208 will clearly increase the value of this program," Sproll said.